NCT07281833: Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
- State
- Under way
- Phase
- Phase 3
- People
- 250 planned
- Started
- 27 Nov 2025
- Primary completion
- Mar 2030
- Arms
- Capivasertib
- Results
- None posted
- 27 Nov 2025: Trial started
- 15 Dec 2025: Trial registered